<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-title>BMC Medicine</journal-title><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19703270</article-id><article-id pub-id-type="pmc">2749039</article-id><article-id pub-id-type="publisher-id">1741-7015-7-42</article-id><article-id pub-id-type="doi">10.1186/1741-7015-7-42</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Zhu</surname><given-names>Andrew X</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>azhu@partners.org</email></contrib></contrib-group><aff id="I1"><label>1</label>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>8</month><year>2009</year></pub-date><volume>7</volume><fpage>42</fpage><lpage>42</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1741-7015/7/42"></ext-link><history><date date-type="received"><day>14</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>24</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Copyright Â© 2009 Zhu; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Zhu; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p><offsets xml_i="2411" xml_f="2777" txt_i="11" txt_f="377">The approval of sorafenib and active development of many other molecularly targeted agents in hepatocellular carcinoma (HCC) have presented a challenge to understand the mechanism of action of sorafenib and identify predictive biomarkers to select patients more likely to benefit from sorafenib. The preclinical study by Zhang and celleagues published this month in </offsets><italic><offsets xml_i="2785" xml_f="2798" txt_i="377" txt_f="390">BMC Medicine </offsets></italic><offsets xml_i="2807" xml_f="3552" txt_i="390" txt_f="1135">provides preliminary evidence that baseline phosphorylated extracellular signaling-regulated kinase (pERK) may be a relevant marker to reflect the level of constitutive activation of the RAF/mitogen-activated protein kinase kinase (MEK)/ERK signaling pathway and has the potential value in predicting response to sorafenib. The clinical data from the initial single arm phase II study and preliminary report from the randomized phase III study also suggest the correlation of baseline archived tumor pERK levels and time to tumor progression in HCC patients. Whether baseline pERK will prove to be a useful predictive biomarker of response and clinical benefits for sorafenib in HCC will need to be validated in future large prospective studies.</offsets></p></abstract></article-meta></front><body><sec><title><offsets xml_i="3608" xml_f="3618" txt_i="1143" txt_f="1153">Commentary</offsets></title><p><offsets xml_i="3629" xml_f="3968" txt_i="1154" txt_f="1493">In 2007, Llovet and colleagues first reported the results of the international, phase III, placebo-controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial, which demonstrated a longer overall survival (OS) time and time to tumor progression (TTP) compared to placebo in patients with advanced hepatocellular carcinoma (HCC) [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="3999" xml_f="4000" txt_i="1493" txt_f="1494">1</offsets></xref><offsets xml_i="4007" xml_f="4028" txt_i="1494" txt_f="1515">]. As shown in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="4060" xml_f="4061" txt_i="1515" txt_f="1516">1</offsets></xref><offsets xml_i="4068" xml_f="4209" txt_i="1516" txt_f="1657">, the median OS time was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio for the sorafenib group, 0.69; </offsets><italic><offsets xml_i="4217" xml_f="4219" txt_i="1657" txt_f="1659">P </offsets></italic><offsets xml_i="4228" xml_f="4331" txt_i="1659" txt_f="1759">&lt; 0.001). The median TTP was 5.5 months in the sorafenib group and 2.8 months in the placebo group (</offsets><italic><offsets xml_i="4339" xml_f="4341" txt_i="1759" txt_f="1761">P </offsets></italic><offsets xml_i="4350" xml_f="4504" txt_i="1761" txt_f="1912">&lt; 0.001). In a subsequent randomized phase III study conducted in Asia, sorafenib also demonstrated a longer OS and TTP in patients with advanced HCC [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="4535" xml_f="4536" txt_i="1912" txt_f="1913">2</offsets></xref><offsets xml_i="4543" xml_f="5081" txt_i="1913" txt_f="2451">]. These studies have led to the timely approval of sorafenib in HCC in many countries worldwide. The development of sorafenib in HCC has several important implications. First, it validates the use of molecularly targeted agents in HCC. Second, it sets a new standard for ongoing and future clinical trials in advanced HCC. Now, the challenge is to understand the mechanism of action of this targeted agent and identify predictive biomarkers to select patients more likely to benefit from sorafenib. In an article published this month in </offsets><italic><offsets xml_i="5089" xml_f="5101" txt_i="2451" txt_f="2463">BMC Medicine</offsets></italic><offsets xml_i="5110" xml_f="5298" txt_i="2463" txt_f="2651">, Zhang and colleagues report their study assessing the potential role of phosphorylated extracellular signaling-regulated kinase (pERK) as a predictive marker in a preclinical HCC model [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5329" xml_f="5330" txt_i="2651" txt_f="2652">3</offsets></xref><offsets xml_i="5337" xml_f="5339" txt_i="2652" txt_f="2654">].</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="5387" xml_f="5394" txt_i="2655" txt_f="2662">Table 1</offsets></label><caption><p><offsets xml_i="5414" xml_f="5468" txt_i="2662" txt_f="2716">Sorafenib HCC Assessment Randomized Protocol (SHARP) [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5499" xml_f="5500" txt_i="2716" txt_f="2717">1</offsets></xref><offsets xml_i="5507" xml_f="5527" txt_i="2717" txt_f="2737">] and Asia-Pacific [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5558" xml_f="5559" txt_i="2737" txt_f="2738">2</offsets></xref><offsets xml_i="5566" xml_f="5573" txt_i="2738" txt_f="2745">] study</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><offsets xml_i="5661" xml_f="5668" txt_i="2747" txt_f="2754">SHARP [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5699" xml_f="5700" txt_i="2754" txt_f="2755">1</offsets></xref><offsets xml_i="5707" xml_f="5708" txt_i="2755" txt_f="2756">]</offsets></td><td></td><td align="left"><offsets xml_i="5739" xml_f="5753" txt_i="2758" txt_f="2772">Asia-Pacific [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5784" xml_f="5785" txt_i="2772" txt_f="2773">2</offsets></xref><offsets xml_i="5792" xml_f="5793" txt_i="2773" txt_f="2774">]</offsets></td><td></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="5848" xml_f="5856" txt_i="2776" txt_f="2784">Endpoint</offsets></td><td align="left"><offsets xml_i="5878" xml_f="5898" txt_i="2785" txt_f="2805">Sorafenib vs placebo</offsets></td><td></td><td align="left"><offsets xml_i="5929" xml_f="5949" txt_i="2807" txt_f="2827">Sorafenib vs placebo</offsets></td><td></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td></td><td align="left"><offsets xml_i="6037" xml_f="6058" txt_i="2831" txt_f="2852">Hazard ratio (95% CI)</offsets></td><td align="center"><italic><offsets xml_i="6090" xml_f="6092" txt_i="2853" txt_f="2855">P </offsets></italic><offsets xml_i="6101" xml_f="6106" txt_i="2855" txt_f="2860">value</offsets></td><td align="left"><offsets xml_i="6128" xml_f="6149" txt_i="2861" txt_f="2882">Hazard ratio (95% CI)</offsets></td><td align="center"><italic><offsets xml_i="6181" xml_f="6183" txt_i="2883" txt_f="2885">P </offsets></italic><offsets xml_i="6192" xml_f="6197" txt_i="2885" txt_f="2890">value</offsets></td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="6267" xml_f="6269" txt_i="2892" txt_f="2894">OS</offsets></td><td align="left"><offsets xml_i="6291" xml_f="6310" txt_i="2895" txt_f="2914">10.7 vs 7.9 months,</offsets><break></break><offsets xml_i="6325" xml_f="6344" txt_i="2914" txt_f="2933">0.69 (0.55 to 0.87)</offsets></td><td align="center"><offsets xml_i="6368" xml_f="6378" txt_i="2934" txt_f="2941">&lt; 0.001</offsets></td><td align="left"><offsets xml_i="6400" xml_f="6419" txt_i="2942" txt_f="2961">6.5 vs 4.2 months, </offsets><break></break><offsets xml_i="6434" xml_f="6453" txt_i="2961" txt_f="2980">0.68 (0.50 to 0.93)</offsets></td><td align="center"><offsets xml_i="6477" xml_f="6482" txt_i="2981" txt_f="2986">0.014</offsets></td></tr><tr><td align="left"><offsets xml_i="6513" xml_f="6517" txt_i="2987" txt_f="2991">TTSP</offsets></td><td align="left"><offsets xml_i="6539" xml_f="6558" txt_i="2992" txt_f="3011">1.08 (0.88 to 1.31)</offsets></td><td align="center"><offsets xml_i="6582" xml_f="6587" txt_i="3012" txt_f="3017">0.768</offsets></td><td align="left"><offsets xml_i="6609" xml_f="6628" txt_i="3018" txt_f="3037">0.90 (0.67 to 1.22)</offsets></td><td align="center"><offsets xml_i="6652" xml_f="6656" txt_i="3038" txt_f="3042">0.50</offsets></td></tr><tr><td align="left"><offsets xml_i="6687" xml_f="6690" txt_i="3043" txt_f="3046">TTP</offsets></td><td align="left"><offsets xml_i="6712" xml_f="6730" txt_i="3047" txt_f="3065">5.5 vs 2.8 months,</offsets><break></break><offsets xml_i="6745" xml_f="6764" txt_i="3065" txt_f="3084">0.58 (0.45 to 0.74)</offsets></td><td align="center"><offsets xml_i="6788" xml_f="6798" txt_i="3085" txt_f="3092">&lt; 0.001</offsets></td><td align="left"><offsets xml_i="6820" xml_f="6838" txt_i="3093" txt_f="3111">2.8 vs 1.4 months,</offsets><break></break><offsets xml_i="6853" xml_f="6872" txt_i="3111" txt_f="3130">0.57 (0.42 to 0.79)</offsets></td><td align="center"><offsets xml_i="6896" xml_f="6906" txt_i="3131" txt_f="3138">&lt; 0.001</offsets></td></tr><tr><td align="left"><offsets xml_i="6937" xml_f="6939" txt_i="3139" txt_f="3141">RR</offsets></td><td align="left"><offsets xml_i="6961" xml_f="6969" txt_i="3142" txt_f="3150">2% vs 1%</offsets></td><td></td><td align="left"><offsets xml_i="7000" xml_f="7012" txt_i="3152" txt_f="3164">3.3% vs 1.3%</offsets></td><td></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="7067" xml_f="7182" txt_i="3166" txt_f="3281">OS = overall survival; RR = response rate; TTP = time to tumor progression; TTSP = time to symptomatic progression.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="7220" xml_f="7765" txt_i="3282" txt_f="3827">Sorafenib is an oral multikinase inhibitor that targets tumor cell proliferation and tumor angiogenesis by inhibiting the serine/threonine kinases Raf-1 and B-Raf through the canonical Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (RAF/mitogen-activated protein kinase kinase (MEK)/ERK) signaling pathway and the receptor tyrosine kinases (RTK) of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor (PDGFR)Î± and Î² and stem cell factor receptor (KIT) [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7796" xml_f="7797" txt_i="3827" txt_f="3828">4</offsets></xref><offsets xml_i="7804" xml_f="7805" txt_i="3828" txt_f="3829">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="7836" xml_f="7837" txt_i="3829" txt_f="3830">5</offsets></xref><offsets xml_i="7844" xml_f="7997" txt_i="3830" txt_f="3983">]. Human HCC tumors have high expression and enhanced activity of mitogen-activated protein kinase (MAPK) compared to the adjacent non-neoplastic liver [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8028" xml_f="8029" txt_i="3983" txt_f="3984">6</offsets></xref><offsets xml_i="8036" xml_f="8146" txt_i="3984" txt_f="4094">]. Furthermore, treatment of HCC cells with a MEK inhibitor reduces cell proliferation and induces apoptosis [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8177" xml_f="8178" txt_i="4094" txt_f="4095">7</offsets></xref><offsets xml_i="8185" xml_f="8266" txt_i="4095" txt_f="4176">], whereas overexpression of activated MEK1 in HepG2 cells enhances tumor growth </offsets><italic><offsets xml_i="8274" xml_f="8282" txt_i="4176" txt_f="4184">in vivo </offsets></italic><offsets xml_i="8291" xml_f="8292" txt_i="4184" txt_f="4185">[</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8323" xml_f="8324" txt_i="4185" txt_f="4186">8</offsets></xref><offsets xml_i="8331" xml_f="8443" txt_i="4186" txt_f="4298">]. Unlike malignant melanoma or other tumor types, BRAF-activating mutations are relatively rare events in HCC [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8474" xml_f="8475" txt_i="4298" txt_f="4299">9</offsets></xref><offsets xml_i="8482" xml_f="8707" txt_i="4299" txt_f="4524">]. However, Raf kinase is overexpressed in a high percentage of human HCC tumors, and the RAF/MEK/ERK pathway can be activated by major etiologic factors such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infection [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8738" xml_f="8739" txt_i="4524" txt_f="4525">9</offsets></xref><offsets xml_i="8746" xml_f="8747" txt_i="4525" txt_f="4526">,</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8779" xml_f="8781" txt_i="4526" txt_f="4528">10</offsets></xref><offsets xml_i="8788" xml_f="8989" txt_i="4528" txt_f="4729">]. In a series of elegant experiments, Liu and colleagues demonstrated that sorafenib inhibited the phosphorylation of MEK and ERK and downregulated cyclin D1 levels in both PLC/PRF/5 and HepG2 cells [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="9021" xml_f="9023" txt_i="4729" txt_f="4731">11</offsets></xref><offsets xml_i="9030" xml_f="9884" txt_i="4731" txt_f="5585">]. Sorafenib also reduced the phosphorylation level of eIF4E and downregulated the antiapoptotic protein Mcl-1 in a MEK/ERK-independent manner. Consistent with the effects on both MEK/ERK-dependent and MEK/ERK-independent signaling pathways, sorafenib inhibited proliferation and induced apoptosis in both HCC cell lines. In the PLC/PRF/5 xenograft model, sorafenib at 30 mg/kg produced complete tumor growth inhibition. Mechanistically, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochemistry), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase-mediated nick-end labeling) in PLC/PRF/5 tumor xenografts. These findings provide strong support that sorafenib could target HCC through inhibition of tumor angiogenesis and tumor cell proliferation.</offsets></p><p><offsets xml_i="9891" xml_f="10378" txt_i="5586" txt_f="6073">The successful clinical development of sorafenib in HCC and the improved understanding of the mechanism of action of sorafenib have raised several critical questions. What are the potential mechanisms of action that lead to the sorafenib-mediated clinical benefits? Is this due to the VEGFR blockage, inhibition of RAF/MEK/ERK signaling pathway, or off target effects? What are the molecular and clinical predictors of benefits of sorafenib in HCC? In an article published this month in </offsets><italic><offsets xml_i="10386" xml_f="10398" txt_i="6073" txt_f="6085">BMC Medicine</offsets></italic><offsets xml_i="10407" xml_f="10542" txt_i="6085" txt_f="6220">, Zhang and colleagues provided evidence to support the notion that pERK might be a useful predictive marker in preclinical HCC model [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="10573" xml_f="10574" txt_i="6220" txt_f="6221">3</offsets></xref><offsets xml_i="10581" xml_f="10704" txt_i="6221" txt_f="6344">]. RAF/MEK/ERK is an important prototypical signal transduction pathway that is aberrantly activated in many malignancies [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="10736" xml_f="10738" txt_i="6344" txt_f="6346">12</offsets></xref><offsets xml_i="10745" xml_f="11093" txt_i="6346" txt_f="6694">]. The MEK homologues MEK1 and MEK2 are dual specificity kinases, uniquely sharing the consensus kinase motifs of both serine/threonine as well as tyrosine kinases. They exhibit a high degree of stringency in their ability to phosphorylate their ERK substrates. Both MEK isoforms sequentially phosphorylate ERK1 and ERK2 at two sites, initially Tyr</offsets><sup><offsets xml_i="11098" xml_f="11102" txt_i="6694" txt_f="6698">185 </offsets></sup><offsets xml_i="11108" xml_f="11123" txt_i="6698" txt_f="6713">followed by Thr</offsets><sup><offsets xml_i="11128" xml_f="11132" txt_i="6713" txt_f="6717">183 </offsets></sup><offsets xml_i="11138" xml_f="11139" txt_i="6717" txt_f="6718">[</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="11171" xml_f="11173" txt_i="6718" txt_f="6720">13</offsets></xref><offsets xml_i="11180" xml_f="11438" txt_i="6720" txt_f="6978">]. Therefore, pERK is a key downstream component of the RAF/MEK/ERK pathway. Once phosphorylated, pERK can be translocated to the nucleus where it can regulate gene expression by phosphorylating and modulating various transcription factors and target genes [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="11470" xml_f="11472" txt_i="6978" txt_f="6980">14</offsets></xref><offsets xml_i="11479" xml_f="11740" txt_i="6980" txt_f="7241">]. The key strategic location of pERK provides the theoretical basis for its potential role to predict response to agents including sorafenib that inhibit the RAF/MEK/ERK pathway. Using different HCC cell lines (SMMC-7721, MHCC97-L, MHCC97-H and HCCLM6), Zhang </offsets><italic><offsets xml_i="11748" xml_f="11753" txt_i="7241" txt_f="7246">et al</offsets></italic><offsets xml_i="11762" xml_f="13048" txt_i="7246" txt_f="8532">. assessed the pERK expression by immunocytochemical quantification and found that basal pERK levels increased stepwise in these cell lines in accordance with their metastatic potential. Sorafenib inhibited ERK phosphorylation in a dose-dependent manner in these cell lines at a concentration between 5 and 20 Î¼M and the degree of inhibition correlated with their basal pERK expression level. They further demonstrated that the effects of sorafenib on cell proliferation correlated significantly with basal pERK levels. To explore if this correlation was linked to pERK, the authors showed that by reducing the basal ERK phosphorylation level in MHCC97-H with U0126, a selective inhibitor of MEK1/2, they could render these cells less sensitive to sorafenib-mediated growth inhibition. These preclinical findings lend support to the initial report from the phase II study of sorafenib in advanced HCC, in which 33 out of 137 enrolled patients had pretreatment archived tumor tissue available for pERK staining and correlative analyses. In the majority of tumor samples, staining was generally most intense within the nucleus of tumor cells and there was a significant difference in TTP between patients with higher tumor cell pERK staining intensity, versus those with lower intensity [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="13080" xml_f="13082" txt_i="8532" txt_f="8534">15</offsets></xref><offsets xml_i="13089" xml_f="13091" txt_i="8534" txt_f="8536">].</offsets></p><p><offsets xml_i="13098" xml_f="13325" txt_i="8537" txt_f="8764">Is the evidence strong enough to support the use of pERK as a predictive biomarker for sorafenib in HCC? Although this is an intuitive biomarker candidate for sorafenib, and the study of Zhang and colleagues provides promising </offsets><italic><offsets xml_i="13333" xml_f="13342" txt_i="8764" txt_f="8773">in vitro </offsets></italic><offsets xml_i="13351" xml_f="13975" txt_i="8773" txt_f="9397">results, much has to be done before pERK evaluation will become a useful biomarker. Future mechanistic study should assess the link of perturbing pERK pathway in each cell line with drug sensitivity. In addition, the expression of other signaling molecules should be evaluated to make certain that the sensitivity to sorafenib is indeed dependent on pERK expression. The clinical evidence to support the use of pERK as a predictive marker for sorafenib in HCC is also preliminary. Future studies should evaluate pERK expression in large numbers of patients and determine if this biomarker has predictive or prognostic value.</offsets></p><p><offsets xml_i="13982" xml_f="14378" txt_i="9398" txt_f="9794">Identification of potential predictive and surrogate markers in patients receiving sorafenib and other targeted agents remains an area of active investigation. In a preliminary presentation at the American Association for the Study of Liver Diseases (ASSLD) meeting in 2008, Llovet and colleagues reported the early results of assessing potential useful predictive biomarkers in the SHARP study [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="14410" xml_f="14412" txt_i="9794" txt_f="9796">16</offsets></xref><offsets xml_i="14419" xml_f="15169" txt_i="9796" txt_f="10546">]. They found that sorafenib significantly decreased plasma levels of soluble c-KIT, sVEGFR2, sVEGFR3 and increased VEGF levels at 12 weeks. HCC patients with baseline high levels of soluble c-KIT showed a trend to better response to sorafenib in terms of OS and TTP. In addition, baseline higher pERK immunostaining correlated with a trend towards longer TTP. We are eagerly waiting the final report of the correlative analyses from this randomized study. Finally, in an attempt to evaluate the mechanisms of action and to identify useful biomarkers, extensive correlative studies have been performed in two phase II studies of sunitinib (a multitargeted tyrosine kinase inhibitor with overlapping but not identical spectrum with sorafenib) in HCC [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="15201" xml_f="15203" txt_i="10546" txt_f="10548">17</offsets></xref><offsets xml_i="15210" xml_f="15211" txt_i="10548" txt_f="10549">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="15243" xml_f="15245" txt_i="10549" txt_f="10551">18</offsets></xref><offsets xml_i="15252" xml_f="15799" txt_i="10551" txt_f="11098">]. They identified associations between soluble c-KIT, interleukin (IL)6 and other cytokines and OS and progression free survival in advanced HCC patients. Collectively, these circulating biomarker data suggest a critical role for the balance between angiogenic and inflammatory pathways in HCC response and resistance to treatment with tyrosine kinase inhibitors. Successful modulation of these inflammatory markers might be critical for achieving treatment response with sunitinib and potentially other antiangiogenic agents including sorafenib.</offsets></p><p><offsets xml_i="15806" xml_f="15840" txt_i="11099" txt_f="11133">In conclusion, the study by Zhang </offsets><italic><offsets xml_i="15848" xml_f="15853" txt_i="11133" txt_f="11138">et al</offsets></italic><offsets xml_i="15862" xml_f="16359" txt_i="11138" txt_f="11635">. provides additional evidence that baseline pERK may be a relevant marker to reflect the level of constitutive activation of the RAF/MEK/ERK signaling pathway and has the potential value in predicting response to sorafenib. The clinical data on the correlation of pERK and TTP is interesting, but preliminary. Whether baseline pERK will prove to be a useful predictive biomarker of response and clinical benefits for sorafenib in HCC will need to be validated in future large prospective studies.</offsets></p></sec><sec><title><offsets xml_i="16381" xml_f="16400" txt_i="11637" txt_f="11656">Competing interests</offsets></title><p><offsets xml_i="16411" xml_f="16464" txt_i="11657" txt_f="11710">AZ works in an advisory role for Bayer and Genentech.</offsets></p></sec><sec><title><offsets xml_i="16486" xml_f="16509" txt_i="11712" txt_f="11735">Pre-publication history</offsets></title><p><offsets xml_i="16520" xml_f="16584" txt_i="11736" txt_f="11800">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1741-7015/7/42/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The author appreciates the critical review and helpful input from Dr. Dan G Duda.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>de Oliveira</surname><given-names>AC</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><name><surname>Porta</surname><given-names>C</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Bolondi</surname><given-names>L</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Seitz</surname><given-names>JF</given-names></name><name><surname>Borbath</surname><given-names>I</given-names></name><name><surname>HÃ¤ussinger</surname><given-names>D</given-names></name><name><surname>Giannaris</surname><given-names>T</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Moscovici</surname><given-names>M</given-names></name><name><surname>Voliotis</surname><given-names>D</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><collab>SHARP Investigators Study Group</collab></person-group><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">18650514</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0708857</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tsao</surname><given-names>CJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tak</surname><given-names>WY</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Burock</surname><given-names>K</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Voliotis</surname><given-names>D</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name></person-group><article-title>Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19095497</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70285-7</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an <italic>in vitro </italic>study</article-title><source>BMC Medicine</source><year>2009</year><volume>7</volume><fpage>41</fpage><pub-id pub-id-type="pmid">19698189</pub-id><pub-id pub-id-type="doi">10.1186/1741-7015-7-41</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>SM</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Wilkie</surname><given-names>D</given-names></name><name><surname>McNabola</surname><given-names>A</given-names></name><name><surname>Rong</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Vincent</surname><given-names>P</given-names></name><name><surname>McHugh</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Shujath</surname><given-names>J</given-names></name><name><surname>Gawlak</surname><given-names>S</given-names></name><name><surname>Eveleigh</surname><given-names>D</given-names></name><name><surname>Rowley</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Adnane</surname><given-names>L</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name><name><surname>Auclair</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>I</given-names></name><name><surname>Gedrich</surname><given-names>R</given-names></name><name><surname>Voznesensky</surname><given-names>A</given-names></name><name><surname>Riedl</surname><given-names>B</given-names></name><name><surname>Post</surname><given-names>LE</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Trail</surname><given-names>PA</given-names></name></person-group><article-title>BAY 43â9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>7099</fpage><lpage>7109</lpage><pub-id pub-id-type="pmid">15466206</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1443</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>SM</given-names></name><name><surname>Adnane</surname><given-names>L</given-names></name><name><surname>Newell</surname><given-names>P</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name></person-group><article-title>Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</article-title><source>Mol Cancer Ther</source><year>2008</year><volume>7</volume><fpage>3129</fpage><lpage>3140</lpage><pub-id pub-id-type="pmid">18852116</pub-id><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0013</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CM</given-names></name><name><surname>McKillop</surname><given-names>IH</given-names></name><name><surname>Cahill</surname><given-names>PA</given-names></name><name><surname>Sitzmann</surname><given-names>JV</given-names></name></person-group><article-title>Increased MAPK expression and activity in primary human hepatocellular carcinoma</article-title><source>Biochem Biophys Res Commun</source><year>1997</year><volume>236</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9223425</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1997.6840</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiesenauer</surname><given-names>CA</given-names></name><name><surname>Yip-Schneider</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Schmidt</surname><given-names>CM</given-names></name></person-group><article-title>Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma</article-title><source>J Am Coll Surg</source><year>2004</year><volume>198</volume><fpage>410</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">14992744</pub-id><pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2003.10.004</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huynh</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Chow</surname><given-names>KH</given-names></name><name><surname>Tan</surname><given-names>PH</given-names></name><name><surname>Soo</surname><given-names>KC</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name></person-group><article-title>Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis</article-title><source>BMC Gastroenterol</source><year>2003</year><volume>3</volume><fpage>19</fpage><pub-id pub-id-type="pmid">12906713</pub-id><pub-id pub-id-type="doi">10.1186/1471-230X-3-19</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tannapfel</surname><given-names>A</given-names></name><name><surname>Sommerer</surname><given-names>F</given-names></name><name><surname>Benicke</surname><given-names>M</given-names></name><name><surname>Katalinic</surname><given-names>A</given-names></name><name><surname>Uhlmann</surname><given-names>D</given-names></name><name><surname>Witzigmann</surname><given-names>H</given-names></name><name><surname>Hauss</surname><given-names>J</given-names></name><name><surname>Wittekind</surname><given-names>C</given-names></name></person-group><article-title>Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma</article-title><source>Gut</source><year>2003</year><volume>52</volume><fpage>706</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">12692057</pub-id><pub-id pub-id-type="doi">10.1136/gut.52.5.706</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>ES</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Koh</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Bae</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>YM</given-names></name></person-group><article-title>Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma</article-title><source>Hepatol Res</source><year>2004</year><volume>29</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">15163433</pub-id><pub-id pub-id-type="doi">10.1016/j.hepres.2004.02.009</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>McNabola</surname><given-names>A</given-names></name><name><surname>Wilkie</surname><given-names>D</given-names></name><name><surname>Wilhelm</surname><given-names>S</given-names></name><name><surname>Lynch</surname><given-names>M</given-names></name><name><surname>Carter</surname><given-names>C</given-names></name></person-group><article-title>Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>11851</fpage><lpage>11858</lpage><pub-id pub-id-type="pmid">17178882</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1377</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sebolt-Leopold</surname><given-names>JS</given-names></name></person-group><article-title>Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>3651</fpage><lpage>3656</lpage><pub-id pub-id-type="pmid">18559577</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0333</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haystead</surname><given-names>TA</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Haystead</surname><given-names></given-names></name><name><surname>Sturgill</surname><given-names>TW</given-names></name></person-group><article-title>Ordered phosphorylation of p42mapk by MAP kinase kinase</article-title><source>FEBS Lett</source><year>1992</year><volume>306</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">1628739</pub-id><pub-id pub-id-type="doi">10.1016/0014-5793(92)80828-5</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>PJ</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><article-title>Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>3291</fpage><lpage>3310</lpage><pub-id pub-id-type="pmid">17496923</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210422</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Amadori</surname><given-names>D</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>De Greve</surname><given-names>J</given-names></name><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Lathia</surname><given-names>C</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>I</given-names></name><name><surname>Moscovici</surname><given-names>M</given-names></name><name><surname>Saltz</surname><given-names>LB</given-names></name></person-group><article-title>Phase II study of sorafenib in patients with advanced hepatocellular carcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>4293</fpage><lpage>4300</lpage><pub-id pub-id-type="pmid">16908937</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.01.3441</pub-id></citation></ref><ref id="B16"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>PeÃ±a</surname><given-names>C</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Lathia</surname><given-names>C</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial</article-title><source>AASLD 59th Annual Meeting, Hepatology</source><year>2008</year></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DePrimo</surname><given-names>SE</given-names></name><name><surname>Cheng</surname><given-names>A</given-names></name><name><surname>Lanzalone</surname><given-names>S</given-names></name><name><surname>Lechuga</surname><given-names>MJ</given-names></name><name><surname>Harmon</surname><given-names>CS</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Raymond</surname><given-names>E</given-names></name><name><surname>Faivre</surname><given-names>SJ</given-names></name></person-group><article-title>Circulating biomarkers of sunitinib in patients with unresectable hepatocellular carcinoma (HCC): Analysis of correlations with outcome and tumor imaging parameters</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4593</fpage></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><name><surname>di Tomaso</surname><given-names>E</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name><name><surname>Catalano</surname><given-names>OA</given-names></name><name><surname>Sindhwani</surname><given-names>V</given-names></name><name><surname>Blaszkowsky</surname><given-names>LS</given-names></name><name><surname>Yoon</surname><given-names>SS</given-names></name><name><surname>Lahdenranta</surname><given-names>J</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Meyerhardt</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Kwak</surname><given-names>EL</given-names></name><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Miksad</surname><given-names>R</given-names></name><name><surname>Abrams</surname><given-names>TA</given-names></name><name><surname>Enzinger</surname><given-names>PC</given-names></name><name><surname>Fuchs</surname><given-names>CS</given-names></name><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>3027</fpage><lpage>3035</lpage><pub-id pub-id-type="pmid">19470923</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2008.20.9908</pub-id></citation></ref></ref-list></back></article>